[HTML][HTML] Informing immunotherapy with multi-omics driven machine learning
Progress in sequencing technologies and clinical experiments has revolutionized
immunotherapy on solid and hematologic malignancies. However, the benefits of …
immunotherapy on solid and hematologic malignancies. However, the benefits of …
[HTML][HTML] Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer
Y Wang, S Huang, X Feng, W Xu, R Luo, Z Zhu… - Frontiers in …, 2023 - frontiersin.org
The use of immune checkpoint inhibitors (ICIs) has become mainstream in the treatment of
non-small cell lung cancer (NSCLC). The idea of harnessing the immune system to fight …
non-small cell lung cancer (NSCLC). The idea of harnessing the immune system to fight …
[HTML][HTML] A novel sub-regional radiomics model to predict immunotherapy response in non-small cell lung carcinoma
J Peng, D Zou, X Zhang, H Ma, L Han, B Yao - Journal of Translational …, 2024 - Springer
Background Identifying precise biomarkers of immunotherapy response for non-small cell
lung carcinoma (NSCLC) before treatment is challenging. This study aimed to construct and …
lung carcinoma (NSCLC) before treatment is challenging. This study aimed to construct and …
[HTML][HTML] Determining the prognosis of Lung cancer from mutated genes using a deep learning survival model: a large multi-center study
J Peng, L Xiao, H Zhu, L Han, H Ma - Cancer Cell International, 2023 - Springer
Background Gene status has become the focus of prognosis prediction. Furthermore, deep
learning has frequently been implemented in medical imaging to diagnose, prognosticate …
learning has frequently been implemented in medical imaging to diagnose, prognosticate …
[PDF][PDF] Artificial Intelligence and Machine Learning in Predicting the Response to Immunotherapy in Non-small Cell Lung Carcinoma: A Systematic Review
Non-small cell lung carcinoma (NSCLC) is a prevalent and aggressive form of lung cancer,
with a poor prognosis for metastatic disease. Immunotherapy, particularly immune …
with a poor prognosis for metastatic disease. Immunotherapy, particularly immune …
Advancing NSCLC treatment with a machine learning-enabled EDC platform: design and implementation
A Ferrarin - 2022 - politesi.polimi.it
Non-small cell lung cancer (NSCLC) is an extremely heterogeneous disease, with inter-
patient variability that makes the selection of a proper treatment difficult for physicians …
patient variability that makes the selection of a proper treatment difficult for physicians …
Decision model for durable clinical benefit from front-or late-line immunotherapy alone or with chemotherapy in non-small cell lung cancer
J Zhao, L Wang, A Zhou, S Wen, W Fang, L Zhang… - Med, 2024 - cell.com
Background Predictive biomarkers and models of immune checkpoint inhibitors (ICIs) have
been extensively studied in non-small cell lung cancer (NSCLC). However, evidence for …
been extensively studied in non-small cell lung cancer (NSCLC). However, evidence for …